Drug Type Small molecule drug |
Synonyms 5-hydroxyeicosapentaenoic acid, 15-HEPE, AF-102 + [1] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC22H34O3 |
InChIKeyDJYKWMOPVZGTRJ-PILRRHKESA-N |
CAS Registry1667760-39-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Sickle Cell | Phase 3 | - | - | |
Diabetes Mellitus, Type 2 | Phase 2 | US | 13 Oct 2020 | |
Diabetes Mellitus, Type 2 | Phase 2 | GE | 13 Oct 2020 | |
Diabetes Mellitus, Type 2 | Phase 2 | DE | 13 Oct 2020 | |
Diabetes Mellitus, Type 2 | Phase 2 | IL | 13 Oct 2020 | |
Diabetes Mellitus, Type 2 | Phase 2 | LV | 13 Oct 2020 | |
Diabetes Mellitus, Type 2 | Phase 2 | CH | 13 Oct 2020 | |
Hypertriglyceridemia | Phase 2 | US | 13 Oct 2020 | |
Hypertriglyceridemia | Phase 2 | GE | 13 Oct 2020 | |
Hypertriglyceridemia | Phase 2 | DE | 13 Oct 2020 |
Phase 2 | 233 | (DS102 2000mg) | ipvediiare(gipuyuewdu) = okqgcqsrky ewrncnsnmp (zcpzwghtte, zcrkludbrk - lqmmlgvexk) View more | - | 01 Jun 2023 | ||
(DS102 4000mg) | ipvediiare(gipuyuewdu) = zwnirjumsg ewrncnsnmp (zcpzwghtte, mhulvjcgoi - louafokitr) View more | ||||||
Phase 2 | 9 | jptjfhtoay(lpdlarrqiy) = qgovsbdyvd frsitxlqqs (yiyhesbhth, vlwvqkslll - tqadniswdp) View more | - | 29 Jul 2022 | |||
- | 96 | Placebo capsules (Placebo) | ubucookxqz(czqgqfhvxu) = zirspgnxqe bqjoolithj (jamkqidhko, zacyclaykv - klmzlndtxp) View more | - | 21 Apr 2022 | ||
(1000 mg Epeleuton) | ubucookxqz(czqgqfhvxu) = bweqyuxlxf bqjoolithj (jamkqidhko, tsyvpgzaqi - ycxnmafqzo) View more | ||||||
NCT02941549 (Pubmed) Manual | Phase 2 | 96 | phmrvqgczu(atlufkqlln) = not improve zbtfciwnok (zixvawptxt ) View more | Positive | 18 Aug 2020 | ||
Placebo |